ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions.
Circulating tumor DNA shows promise for predicting colorectal cancer outcomes, though its clinical value in decision-making remains uncertain.
This review summarizes circulating tumor DNA evidence across resectable and advanced colorectal cancer. It supports prognostic use while emphasizing that clinical utility and outcome benefit remain incompletely proven.
What the study was
- Study design
- Structured narrative review
- Population
- Patients with resectable or advanced colorectal cancer
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- OncoTargets and therapy
Why it surfaced
The article is highly relevant to liquid-biopsy surveillance and carefully separates prognostic validity from proven clinical utility, but it is a review rather than new prospective evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.